Lipid nanoparticle-points to consider in assessing materials quality for ribonucleic acid-based therapeutics

Area of Science:

• Biotechnology
• Pharmaceutics
• Nanomedicine

Background:

• Lipid nanoparticles (LNPs) are a leading nonviral delivery system for ribonucleic acid (RNA)-based therapeutics.
• LNPs offer advantages over traditional methods, including enhanced cellular uptake, reduced toxicity, and protection of RNA cargo.
• Their tunable composition allows for precise control over pharmacokinetics, immunogenicity, and tissue targeting.

Purpose of the Study:

• To provide a comprehensive overview of LNP delivery systems for RNA therapeutics.
• To discuss critical components, design considerations, and formulation complexities of LNPs.
• To highlight current regulatory challenges and the need for standardized frameworks.

Main Methods:

• Review of LNP components, focusing on messenger RNA, guide RNA, and lipid elements.
• Discussion of prophylactic versus therapeutic formulations and quality attributes.
• Analysis of LNP formulation, characterization, production, and quality control.

Main Results:

• LNPs facilitate endosomal escape, improving transfection efficiency and therapeutic index.
• LNP-based delivery offers advantages over viral vectors, including cost-effectiveness and scalability.
• Key quality and purity attributes are essential for safe and effective LNP use.

Conclusions:

• Robust quality standards and regulatory clarity are vital as novel RNA modalities emerge.
• Collaboration between industry and regulatory bodies is urgently needed to establish a harmonized LNP development framework.
• Optimizing LNP formulations is essential for ensuring the safety, efficacy, and rapid translation of RNA-LNP therapeutics.